MYC and lymphoma: A Clinico-Genotypic Index (CGI) was derived from point-wise addition of all 5 unique adverse parameters from the 2 multivariate analyses above (presence of B-symptoms at diagnosis, stage 3–4 lymphoma, presence of BCL6 and/or MYC rearrangement, non-CR response to first-line chemotherapy and use of other chemotherapy regimen from R-CHOP) with score classifications of 0–1 (low risk), 2 (low-intermediate risk), 3 (high-intermediate risk) and 4–5 (high risk).